The Impact of Intratympanic Steroid Dosage on Hearing Recovery in Sudden Sensorineural Hearing Loss
Annals of Otology, Rhinology & Laryngology · 2023-08 · 132 (8) · 879-887
DOI: 10.1177/00034894221120125 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Otology, Rhinology & Laryngology, online erschienen am 21.08.2022. Verfasst von Lacey Nelson und 7 weiteren Autor:innen. Beteiligte Einrichtung: Georgetown University School of Medicine, Washington, DC, USA. Hauptthemen laut MEDLINE: Hearing Loss, Sudden, Hearing Loss, Sensorineural. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 34 Literaturangaben.
Abstract (Originalsprache)
Objective
To investigate how dexamethasone dosage impacts intratympanic steroid therapy (IST) for treatment of sudden sensorineural hearing loss (SSNHL). Study Design: Retrospective review.
Methods
Inclusion criteria identified subjects who received IST between January 1, 2010 and June 1, 2020 for iSSNHL. Subjects with Meniere’s disease, autoimmune inner ear disease, subjects who received injections of non-dexamethasone steroid formulations, and subjects with missing audiogram data were excluded. Subjects were stratified by dexamethasone dosage: low-dose (10 mg/ml) versus high-dose (24 mg/ml), time-to-treatment and oral corticosteroid use. Outcome measures included post-treatment improvement in 4-frequency pure tone average (4F-PTA [500, 1000, 2000,4000 Hz]), low- and high-frequency PTA (250-1000 Hz and 2000-8000 Hz, respectively).
Results
Of the 55 included subjects (50.9% male, mean age 48.9 ± 16.4 years), 31 received high-dose while 24 received low-dose injections. 90.9% of subjects were treated with oral steroids prior to or during IST. No significant differences in hearing outcomes were observed between low- and high-dose cohorts or when stratifying by oral steroid use. Time-to-treatment analysis comparing ≤1 month (67.3%) versus >1 month (32.7%) groups demonstrated a significant improvement in post-treatment 4F-PTA ( P = .01) in the ≤1 month group.
Conclusions
Hearing recovery was not significantly different between the 10 mg/ml versus 24 mg/ml doses of intratympanic dexamethasone, suggesting that steroid dose may not impact the efficacy of IST. A shorter time-to-treatment was observed to be favorable for hearing improvement.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Georgetown University School of Medicine, Washington, DC, USA.
- Department of Otolaryngology-Head and Neck Surgery, Georgetown University Medical Center, Washington, DC, USA.
- Department of Biostatistics, Bioinformatics and Biomathematics, Georgetown University Medical Center, Washington, DC, USA.
ORCID-Profile: Lacey Nelson, Elizabeth Borowiec, Xue Geng
Zitieren
APA
Nelson, L., Swanson, D., Borowiec, E., Crossley, J., Geng, X., Cao, X., Kim, H. J., & Hoa, M. (2023). The Impact of Intratympanic Steroid Dosage on Hearing Recovery in Sudden Sensorineural Hearing Loss. Annals of Otology, Rhinology & Laryngology, 132(8), 879-887. https://doi.org/10.1177/00034894221120125
Vancouver
Nelson L, Swanson D, Borowiec E, Crossley J, Geng X, Cao X, et al. The Impact of Intratympanic Steroid Dosage on Hearing Recovery in Sudden Sensorineural Hearing Loss. Annals of Otology, Rhinology & Laryngology. 2023;132(8):879-887. doi:10.1177/00034894221120125
BibTeX
@article{Nelson2023,
author = {Nelson, Lacey and Swanson, Daniel and Borowiec, Elizabeth and Crossley, Jason and Geng, Xue and Cao, Xiao and Kim, Hung Jeffrey and Hoa, Michael},
title = {The Impact of Intratympanic Steroid Dosage on Hearing Recovery in Sudden Sensorineural Hearing Loss},
journal = {Annals of Otology, Rhinology & Laryngology},
year = {2023},
volume = {132},
number = {8},
pages = {879--887},
doi = {10.1177/00034894221120125}
}
EUVIMED